On October 6, Iovance Biotherapeutics, Inc. fell 5.27% in regular trading, trading at $13.335 per share with turnover of $42.9533 million. The decline followed the company's October 1 announcement appointing Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer, which came after a sharp rally exceeding 35% triggered by raised 2026 revenue guidance.

The company recently lifted its 2026 revenue outlook to $410 million to $420 million, up from $350 million to $370 million, citing strong U.S. demand for Amtagvi and Proleukin. Analyst estimates had averaged $402.8 million. The CMO appointment, made during a period of rapid share appreciation, prompted profit-taking as the market consolidated recent gains.

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocytes for metastatic melanoma and other solid tumor cancers in the United States. Its portfolio includes Amtagvi, Proleukin, and multiple pipeline candidates for lung and gynecological cancers.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)